AU9742298A - Parasiticidal formulations - Google Patents

Parasiticidal formulations Download PDF

Info

Publication number: AU9742298A
Authority: AU; Australia
Prior art keywords: implant; parasiticidal compound; parasiticidal; tabletting; implants
Prior art date: 1997-09-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU97422/98A

Other languages

English (en)

Inventor

Hiep Huatan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Corp SRL

Original Assignee

Pfizer Corp Belgium

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-23

Filing date

1998-09-04

Publication date

1999-04-12

1997-09-23 Priority claimed from GBGB9720228.7A external-priority patent/GB9720228D0/en

1998-05-12 Priority claimed from GBGB9810143.9A external-priority patent/GB9810143D0/en

1998-09-04 Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium

1999-04-12 Publication of AU9742298A publication Critical patent/AU9742298A/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 32
230000000590 parasiticidal effect Effects 0.000 title claims description 19
238000009472 formulation Methods 0.000 title claims description 13
239000007943 implant Substances 0.000 claims description 70
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 19
QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 19
235000019359 magnesium stearate Nutrition 0.000 claims description 18
239000004255 Butylated hydroxyanisole Substances 0.000 claims description 16
235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 16
229960003997 doramectin Drugs 0.000 claims description 15
239000005660 Abamectin Substances 0.000 claims description 13
FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
239000003963 antioxidant agent Substances 0.000 claims description 9
238000002156 mixing Methods 0.000 claims description 9
241000283690 Bos taurus Species 0.000 claims description 8
RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 8
230000003078 antioxidant effect Effects 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
238000002513 implantation Methods 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
239000004067 bulking agent Substances 0.000 claims description 5
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 5
229940043253 butylated hydroxyanisole Drugs 0.000 claims description 5
239000003638 chemical reducing agent Substances 0.000 claims description 5
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
239000007885 tablet disintegrant Substances 0.000 claims description 5
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
208000030852 Parasitic disease Diseases 0.000 claims description 4
235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
230000015556 catabolic process Effects 0.000 claims description 4
238000006731 degradation reaction Methods 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
239000008109 sodium starch glycolate Substances 0.000 claims description 4
229940079832 sodium starch glycolate Drugs 0.000 claims description 4
229920003109 sodium starch glycolate Polymers 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
241001494479 Pecora Species 0.000 claims description 2
229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
210000005069 ears Anatomy 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
230000001954 sterilising effect Effects 0.000 claims 2
238000004659 sterilization and disinfection Methods 0.000 claims 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000008187 granular material Substances 0.000 description 8
238000005469 granulation Methods 0.000 description 7
230000003179 granulation Effects 0.000 description 7
235000006708 antioxidants Nutrition 0.000 description 6
239000011230 binding agent Substances 0.000 description 5
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 4
241000237858 Gastropoda Species 0.000 description 4
230000037058 blood plasma level Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 3
241000238876 Acari Species 0.000 description 3
229960004977 anhydrous lactose Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229960002418 ivermectin Drugs 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
244000000013 helminth Species 0.000 description 2
HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
244000045947 parasite Species 0.000 description 2
238000009304 pastoral farming Methods 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
ZRADTNJSPQDCDV-UHFFFAOYSA-N 2-butyl-4-methoxyphenol Chemical compound CCCCC1=CC(OC)=CC=C1O ZRADTNJSPQDCDV-UHFFFAOYSA-N 0.000 description 1
IMOYOUMVYICGCA-UHFFFAOYSA-N 2-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C=C1C(C)(C)C IMOYOUMVYICGCA-UHFFFAOYSA-N 0.000 description 1
VARHUCVRRNANBD-PVVXTEPVSA-N 22,23-dihydroavermectin B1b Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C VARHUCVRRNANBD-PVVXTEPVSA-N 0.000 description 1
241000234642 Festuca Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
208000006968 Helminthiasis Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
241000920471 Lucilia caesar Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
241001674048 Phthiraptera Species 0.000 description 1
241000258242 Siphonaptera Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000013543 active substance Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
-1 alkyl gallate derivatives Chemical class 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940091906 dectomax Drugs 0.000 description 1
RMGVZKRVHHSUIM-UHFFFAOYSA-L dithionate(2-) Chemical compound [O-]S(=O)(=O)S([O-])(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-L 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
244000078703 ectoparasite Species 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
244000079386 endoparasite Species 0.000 description 1
HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229960003951 masoprocol Drugs 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000003801 milling Methods 0.000 description 1
208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
239000002297 parasiticide Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000008359 toxicosis Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU97422/98A 1997-09-23 1998-09-04 Parasiticidal formulations Abandoned AU9742298A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB9720228		1997-09-23
GBGB9720228.7A GB9720228D0 (en)	1997-09-23	1997-09-23	Parasiticidal formulations
GB9810143		1998-05-12
GBGB9810143.9A GB9810143D0 (en)	1998-05-12	1998-05-12	Parasiticidal formulations
PCT/EP1998/005720 WO1999015166A1 (en)	1997-09-23	1998-09-04	Parasiticidal formulations

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002300653A Division AU2002300653A1 (en)	1997-09-23	2002-08-20	Parasiticidal Formulations

Publications (1)

Publication Number	Publication Date
AU9742298A true AU9742298A (en)	1999-04-12

Family

ID=26312302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU97422/98A Abandoned AU9742298A (en)	1997-09-23	1998-09-04	Parasiticidal formulations

Country Status (13)

Country	Link
EP (1)	EP1014970A1 (pt)
JP (1)	JP2001517622A (pt)
AP (1)	AP9801350A0 (pt)
AR (1)	AR013509A1 (pt)
AU (1)	AU9742298A (pt)
BR (1)	BR9812385A (pt)
CA (1)	CA2304283A1 (pt)
GT (1)	GT199800149A (pt)
MA (1)	MA24655A1 (pt)
PA (1)	PA8459501A1 (pt)
PE (1)	PE117199A1 (pt)
TN (1)	TNSN98175A1 (pt)
WO (1)	WO1999015166A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP279698A0 (en) *	1998-04-03	1998-04-30	Sunscape Developments Limited	Sustained release formulation
US6645192B2 (en)	1998-09-30	2003-11-11	Ivy Animal Health, Inc.	Pellet implant system for immediate and delayed release of antiparasitic drug
AU1556000A (en) *	1999-11-22	2001-06-04	Akzo Nobel N.V.	Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US6953586B1 (en)	2000-06-08	2005-10-11	Ivy Animal Health, Inc.	Growth promoting pharmaceutical implant
DE10032878A1 (de) *	2000-07-06	2002-01-17	Bayer Ag	Anthelmintika zur Verhinderung von parasitären Infektionen bei Mensch und Tier
AUPR602501A0 (en) *	2001-06-29	2001-07-26	Smart Drug Systems Inc	Sustained release pharmaceutical composition
AUPR602401A0 (en) *	2001-06-29	2001-07-26	Smart Drug Systems Inc	Sustained release delivery system
AUPR610501A0 (en) *	2001-07-04	2001-07-26	Smart Drug Systems Inc	Treatment of parasitic disease
US7918863B2 (en)	2005-06-24	2011-04-05	Conceptus, Inc.	Minimally invasive surgical stabilization devices and methods
EP3634583A4 (en) *	2017-06-06	2021-03-03	Merck Sharp & Dohme Corp.	LONG-LASTING EFFECT IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0240274A3 (en) *	1986-04-03	1990-03-14	Merck & Co. Inc.	Avermectins as growth promotant agents
US4847243A (en) *	1987-10-08	1989-07-11	Merck & Co., Inc.	Treatment for fescue toxicosis in grazing animals
NZ239370A (en) *	1990-08-22	1994-04-27	Merck & Co Inc	Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
US5411737A (en) *	1991-10-15	1995-05-02	Merck & Co., Inc.	Slow release syneresing polymeric drug delivery device

1998
- 1998-09-04 CA CA002304283A patent/CA2304283A1/en not_active Abandoned
- 1998-09-04 JP JP2000512535A patent/JP2001517622A/ja active Pending
- 1998-09-04 AU AU97422/98A patent/AU9742298A/en not_active Abandoned
- 1998-09-04 EP EP98951367A patent/EP1014970A1/en not_active Withdrawn
- 1998-09-04 WO PCT/EP1998/005720 patent/WO1999015166A1/en not_active Ceased
- 1998-09-04 BR BR9812385-8A patent/BR9812385A/pt not_active IP Right Cessation
- 1998-09-17 AP APAP/P/1998/001350A patent/AP9801350A0/en unknown
- 1998-09-17 PA PA19988459501A patent/PA8459501A1/es unknown
- 1998-09-21 AR ARP980104712A patent/AR013509A1/es unknown
- 1998-09-22 MA MA25268A patent/MA24655A1/fr unknown
- 1998-09-22 GT GT199800149A patent/GT199800149A/es unknown
- 1998-09-22 TN TNTNSN98175A patent/TNSN98175A1/fr unknown
- 1998-09-22 PE PE1998000903A patent/PE117199A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2304283A1 (en)	1999-04-01
PE117199A1 (es)	1999-11-20
PA8459501A1 (es)	2000-05-24
WO1999015166A1 (en)	1999-04-01
TNSN98175A1 (fr)	2005-03-15
GT199800149A (es)	2000-03-15
BR9812385A (pt)	2000-09-12
AR013509A1 (es)	2000-12-27
EP1014970A1 (en)	2000-07-05
AP9801350A0 (en)	2000-03-17
JP2001517622A (ja)	2001-10-09
MA24655A1 (fr)	1999-04-01

Publication	Publication Date	Title
EP1035835B1 (en)	2003-09-10	Long acting injectable formulations containing hydrogenated castor oil
US6653288B1 (en)	2003-11-25	Injectable anthelmintic compositions and methods for using same
KR20120006987A (ko)	2012-01-19	마크로시클릭 락톤 약물 전달 시스템
AU9742298A (en)	1999-04-12	Parasiticidal formulations
KR20100020003A (ko)	2010-02-19	안정한 비수성 외용제 조성물
CA2202707C (en)	2000-07-18	Non-aqueous oral-drench compositions containing avermectin compounds
DE69221454T2 (de)	1997-12-11	Systemisch gegen Ektoparasiten anwendbare Juvenilhormone
CN1822880B (zh)	2012-07-11	杀灭寄生物的组合物
US20040247634A1 (en)	2004-12-09	Treatment of parasitic disease
KR20150094643A (ko)	2015-08-19	향상된 수용성 및 우수한 저장 안정성을 가지는 정제
EP2598151B1 (en)	2018-12-26	Compositions for treating heartworm infestation
MXPA00002843A (en)	2001-12-13	Parasiticidal formulations
EP3609470B1 (en)	2023-11-22	Implant for treating parasites infestations
US6953586B1 (en)	2005-10-11	Growth promoting pharmaceutical implant
CN110022862B (zh)	2022-05-24	药物制剂及其制造方法
HK40099580A (zh)	2024-04-19	适口调配物
AU709310B2 (en)	1999-08-26	Non-aqueous oral-drench compositions containing avermectin compounds
CN121445875A (zh)	2026-02-03	犬用大环内酯与异噁唑啉类药物组合局部外用制剂、制备方法及应用
HK40011796A (en)	2020-07-17	Pharmaceutical preparation and method for its manufacture
HK1096621B (en)	2013-01-18	Parasiticidal composition
AU5995999A (en)	2000-06-13	Antiparasitic formulations

Legal Events

Date	Code	Title	Description
2002-09-26	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted